Trials / Recruiting
RecruitingNCT07116915
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation and inhalation suspension administered in a single dose in healthy individuals and multiple doses in patients with COPD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension | HRS-9821 Powder for Inhalation. HRS-9821 inhalation suspension |
| DRUG | HRS-9821 Powder for Inhalation placebo/HRS-9821 inhalation suspension placebo | HRS-9821 Powder for Inhalation placebo. HRS-9821 inhalation suspension placebo |
| DRUG | Moxifloxacin Hydrochloride Tablets | Moxifloxacin Hydrochloride Tablets |
Timeline
- Start date
- 2025-08-11
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2025-08-12
- Last updated
- 2026-02-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07116915. Inclusion in this directory is not an endorsement.